Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12

Table 1 Characteristics of study cohort patients

Demographics
n		260
Age	(yr)1	53 (44-60)
Sex	Male/Female n (%)	157 (60)/103 (40)
Baseline viral characteristics
Genotype 1a/1b/1x	n (%)/n (%)/n (%)	76 (29)/115 (44)/3(1)
Genotype 2/3	n (%)/n (%)	8 (3)/44 (17)
Genotype 4/5/6	n (%)/n (%)	11 (4)/1 (0.4)/2 (0.8)
Baseline viral load	(IU/mL)1	1.33 Mio. (414.750-3.4 Mio.)
Baseline viral load ≥ 800.000 IU/mL	n (%)	169 (65)
Baseline viral load ≥ 6 Mio IU/mL	n (%)	28 (11)
Special populations
LCi2	n (%)	89 (34)
Low platelets ( ≤ 100/nL)	n (%)	56 (22)
Post Liver Transplantation	n (%)	17 (7)
Patients ≥ 60 yr	n (%)	72 (28)
Patients with MELD score ≥ 10	n (%)	25 (10)
Treatment history
Treatment experienced	n (%)	144 (55)
Treatment regimens [thereof liver cirrhosis n (%)]
SOF PR	n (%)/LCi n (%)	51 (20)/6 (12)
SOF R	n (%)/LCi n (%)	10 (4)/4 (40)
SOF SMV	n (%)/LCi n (%)/R n (%)	30 (12)/16 (53)/15 (19)
SOF DCV	n (%)/LCi n (%)/R n (%)	81 (31)/42 (52)/12 (40)
SOF LDV	n (%)/LCi n (%)/R n (%)	73 (28)/17 (23)/16 (22)
3D	n (%)/LCi n (%)/R n (%)	15 (6)/4 (27)/6 (40)
Baseline clinical chemistry
WBC	(/μL)1	5935 (4683-7670)
Hemoglobin	(g/dL)1	14.5 (13.1-15.6)
Platelets	(thousand/μL)1	174 (113-228)
Creatinine	(mg/dL)1	0.7 (0.6-0.8)
Total Bilirubin	(mg/dL)1	0.7 (0.5-1.0)
INR	INR1	1 (1-1)
ALT	IU/l1	67 (44-105)

¹Data are presented as medians (interquartile ranges in parentheses);

²By liver histology, Fibroscan (> 12.5 kPa), or by clinical diagnosis (e.g., esophageal varices, ascites, distinct ultrasound signs of portal hypertension or liver cirrhosis). 1x: Genotype 1, no subtype differentiable; LCi: Liver cirrhosis; MELD: Model of end stage liver disease; P: Pegylated Interferon; R: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; DCV: Daclatasvir; 3D: Dasabuvir, Ombitasvir, and Paritaprevir/r; WBC: White blood cell count; INR: International normalized ratio; ALT: Alanine-aminotransferase.